Development of Radiohalogenated Osimertinib Derivatives as Imaging Probes for Companion Diagnostics of Osimertinib-Reference-Cited by-同舟云学术

Development of Radiohalogenated Osimertinib Derivatives as Imaging Probes for Companion Diagnostics of Osimertinib

Published:2022-01-11 Issue:3 Volume:65 Page:1835-1847
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Mishiro Kenji¹^ORCID,Nishii Ryuichi²,Sawazaki Izumi³,Sofuku Tomoki³,Fuchigami Takeshi³,Sudo Hitomi²,Effendi Nurmaya¹,Makino Akira⁴^ORCID,Kiyono Yasushi⁴,Shiba Kazuhiro⁵,Taki Junichi⁶,Kinuya Seigo⁶,Ogawa Kazuma¹³^ORCID

Affiliation:

1. Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan

2. Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST) Chiba, Inage-ku, Chiba 263-8555, Japan

3. Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan

4. Biomedical Imaging Research Center, University of Fukui, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan

5. Research Center for Experimental Modeling of Human Disease, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8640, Japan

6. Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8641, Japan

Funder

Ministry of Education, Culture, Sports, Science and Technology

Terumo Foundation for Life Sciences and Arts

Kanazawa University

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01211

Reference40 articles.

1. Cancer statistics, 2020